课题基金 / 基金详情

Molecular Ontogeny of Oral Mucosal Resistance to SIV

Molecular Ontogeny of Oral Mucosal Resistance to SIV
口腔粘膜对 SIV 耐药性的分子个体发育
批准号:
6994462
负责人:
MICHAEL E SELSTED
金额:
$55.97万
依托单位国家:
美国
项目类别:
财政年份:
2003
资助国家:
美国
项目状态:
已结题
起止时间:
2003-12-15 至 2007-11-30

项目摘要

项目成果

MICHAEL E SELSTED的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Epidemiologic studies demonstrate that the oral cavity of human adults is relatively resistant to HIV infection, and a number of soluble factors present in saliva have been postulated to confer this protection. In contrast, oral infection of infants who are breast fed by HIV-infected mothers is quite common, suggesting that there are age dependent differences in oral resistance to lentiviruses. We will investigate the basis of these age-dependent differences in antiviral resistance by characterizing anti-SIV innate immunity in the oral cavity of rhesus macaques. The long term goal of the proposed studies is to delineate the anti-HIV role of defensins, antiviral peptides now known to be present in saliva and expressed in epithelium of the oral cavity. Three human defensins were recently identified as anti-HIV factors produced by CD-8+ T cells from HIV-positive individuals who are long term non-progressors. We hypothesize that defensins conlribute to the anti-SIV/HW properties of saliva and to the innate resistance of oral mucosa, 2) that oral defensin expression develops postnatally, and 3) that the level of oral resistance to SIV in neonates may be augmented by topical application of one or more defensins. To test these hypotheses, we will pursue the following Specific Aims: ? Specific Aim 1 is to determine the level of alpha, beta,and theta-defensins present in saliva and/or expressed in the oral cavity of infant and adult rhesus macaques. ? Specific Aim 2 is to synthesize and/or recombinantly express specific alpha, beta, and theta-defensins confirmed (in Specific Aim 1) to be components of adult saliva and/or expressed in oral tissues. Peptides thus produced will be fully characterized and evaluated for their anti-SIV efficacy (Specific Aim 3), and will be used to produce anti-peptide immunologic reagents. ? Specific Aim 3 is to determine the anti-SIV and anti-HIV activities of oral alpha, beta,and theta-defensins in vitro. Anti-HW assays will be conducted with and without neonatal and adult saliva to ascertain the effect of this natural fluid on peptide activities. Combinations of peptides will also be analyzed to detect additive or synergistic pepfide-peptide interactions. ? Specific Aim 4 is to determine whether exogenous, topically administered defensin can alter the susceptibility to infection of neonatal rhesus macaques.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Regulation of Mucosal Immunity by Pro- and Anti-inflammatory Salivary Defensins
  • 批准号:
    8127613
  • 项目类别:
  • 资助金额:
    $38.11万
  • 财政年份:
    2010
  • 负责人:
    MICHAEL E SELSTED
  • 依托单位:
Regulation of Mucosal Immunity by Pro- and Anti-inflammatory Salivary Defensins
  • 批准号:
    8665891
  • 项目类别:
  • 资助金额:
    $38.89万
  • 财政年份:
    2010
  • 负责人:
    MICHAEL E SELSTED
  • 依托单位:
Regulation of Mucosal Immunity by Pro- and Anti-inflammatory Salivary Defensins
  • 批准号:
    8269132
  • 项目类别:
  • 资助金额:
    $38.89万
  • 财政年份:
    2010
  • 负责人:
    MICHAEL E SELSTED
  • 依托单位:
Regulation of Mucosal Immunity by Pro- and Anti-inflammatory Salivary Defensins
  • 批准号:
    8462591
  • 项目类别:
  • 资助金额:
    $37.34万
  • 财政年份:
    2010
  • 负责人:
    MICHAEL E SELSTED
  • 依托单位:
国内基金
海外基金
Lentivirus载体转染骨髓间质干细胞诱导增殖和成骨细胞定向分化修复骨缺损的研究
  • 批准号:
    30371434
  • 项目类别:
    面上项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2003
  • 负责人:
    姜建元
  • 依托单位: